Accelerated fractionation versus conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study: Japan Clinical Oncology Group study (JCOG 0701)

Jpn J Clin Oncol. 2008 May;38(5):387-9. doi: 10.1093/jjco/hyn025. Epub 2008 Apr 3.


A randomized Phase III study was started in Japan to demonstrate the non-inferiority of survival of accelerated fractionation radiation therapy (2.4 Gy/fr) with conventional fractionation radiation therapy (2 Gy/fr) in patients with T1-2N0M0 glottic cancer. This study began in September 2007, and a total of 360 patients will be accrued from 22 institutions within 4 years. The primary endpoint is 3-year progression-free survival (PFS). The secondary endpoints are overall survival, local progression-free survival, disease-free survival, survival with preserved voice function, complete response rate, proportion of treatment completion and adverse events.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Disease-Free Survival
  • Dose Fractionation, Radiation*
  • Female
  • Glottis*
  • Humans
  • Japan
  • Laryngeal Neoplasms / pathology*
  • Laryngeal Neoplasms / physiopathology
  • Laryngeal Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy / adverse effects
  • Radiotherapy / methods
  • Radiotherapy Dosage
  • Survival Analysis
  • Treatment Outcome
  • Voice Disorders / prevention & control